Regarding enrollment in the EB101 vital trial, we remain on track for activating a second study site in the northeast to complement Stanford on the west coast in the second half of 21 Patient and physician interest in the study continues to be high, and we're observing a greater willingness to travel on what we believe is the growing percentage of the population starting to receive vaccines for COVID-19.

May 25, 2021 / CEO / receipt, needs a key / Michael Amoroso, CEO | earnings call 2021-05-25 | transcript f09400aa-33e4-4875-b2d1-151b57464140 | chars 8025-8432 | segment 7